MedTrace Logo

Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00002911 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-12-18

No results posted yet for this study

Summary

RATIONALE: Marimastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor.

PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of marimastat in treating patients who have residual stage III non-small cell lung cancer.

Conditions

Interventions

DRUG

marimastat

Sponsors & Collaborators

  • ILEX Oncology Services, Incorporated

    lead INDUSTRY

Principal Investigators

  • Kathleen Heck, MEd, MBA · ILEX Oncology Services, Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-12-31
Completion
2004-05-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002911 on ClinicalTrials.gov